 Leukemia, Myeloid, Acute
"Leukemia, Myeloid, Acute" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
| Descriptor ID |
D015470
|
| MeSH Number(s) |
C04.557.337.539.275
|
| Concept/Terms |
Leukemia, Myeloid, Acute- Leukemia, Myeloid, Acute
- Acute Myeloid Leukemia
- Acute Myeloid Leukemias
- Leukemias, Acute Myeloid
- Myeloid Leukemias, Acute
- ANLL
- Leukemia, Acute Myelogenous
- Leukemia, Acute Myeloid
- Leukemia, Myeloblastic, Acute
- Leukemia, Myelocytic, Acute
- Leukemia, Myelogenous, Acute
- Leukemia, Nonlymphoblastic, Acute
- Leukemia, Nonlymphocytic, Acute
- Myeloblastic Leukemia, Acute
- Acute Myeloblastic Leukemia
- Acute Myeloblastic Leukemias
- Leukemia, Acute Myeloblastic
- Leukemias, Acute Myeloblastic
- Myeloblastic Leukemias, Acute
- Myelocytic Leukemia, Acute
- Acute Myelocytic Leukemia
- Acute Myelocytic Leukemias
- Leukemia, Acute Myelocytic
- Leukemias, Acute Myelocytic
- Myelocytic Leukemias, Acute
- Myelogenous Leukemia, Acute
- Myeloid Leukemia, Acute
- Nonlymphoblastic Leukemia, Acute
- Acute Nonlymphoblastic Leukemia
- Acute Nonlymphoblastic Leukemias
- Leukemia, Acute Nonlymphoblastic
- Leukemias, Acute Nonlymphoblastic
- Nonlymphoblastic Leukemias, Acute
- Nonlymphocytic Leukemia, Acute
- Acute Nonlymphocytic Leukemia
- Acute Nonlymphocytic Leukemias
- Leukemia, Acute Nonlymphocytic
- Leukemias, Acute Nonlymphocytic
- Nonlymphocytic Leukemias, Acute
- Acute Myelogenous Leukemia
- Acute Myelogenous Leukemias
- Leukemias, Acute Myelogenous
- Myelogenous Leukemias, Acute
|
Below are MeSH descriptors whose meaning is more general than "Leukemia, Myeloid, Acute".
Below are MeSH descriptors whose meaning is more specific than "Leukemia, Myeloid, Acute".
- Leukemia, Myeloid, Acute
- Leukemia, Basophilic, Acute
- Leukemia, Eosinophilic, Acute
- Leukemia, Erythroblastic, Acute
- Leukemia, Mast-Cell
- Leukemia, Megakaryoblastic, Acute
- Leukemia, Monocytic, Acute
- Leukemia, Promyelocytic, Acute
This graph shows the total number of publications written about "Leukemia, Myeloid, Acute" by people in this website by year, and whether "Leukemia, Myeloid, Acute" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 | | 2001 | 2 | 0 | 2 | | 2002 | 1 | 0 | 1 | | 2003 | 1 | 0 | 1 | | 2004 | 4 | 1 | 5 | | 2005 | 2 | 0 | 2 | | 2006 | 4 | 1 | 5 | | 2007 | 4 | 1 | 5 | | 2008 | 5 | 0 | 5 | | 2009 | 3 | 3 | 6 | | 2010 | 7 | 1 | 8 | | 2011 | 9 | 0 | 9 | | 2012 | 8 | 2 | 10 | | 2013 | 15 | 1 | 16 | | 2014 | 10 | 2 | 12 | | 2015 | 13 | 1 | 14 | | 2016 | 15 | 5 | 20 | | 2017 | 23 | 3 | 26 | | 2018 | 28 | 6 | 34 | | 2019 | 30 | 1 | 31 | | 2020 | 21 | 1 | 22 | | 2021 | 32 | 2 | 34 | | 2022 | 30 | 1 | 31 | | 2023 | 30 | 0 | 30 | | 2024 | 22 | 5 | 27 | | 2025 | 21 | 0 | 21 | | 2026 | 10 | 0 | 10 |
To return to the timeline, click here.
Below are the most recent publications written about "Leukemia, Myeloid, Acute" by people in Profiles.
-
Pastrana CC, Nonavinkere Srivatsan S, Alberti MO, Hossan T, Ahmed T, Shao J, Chavez M, Grieb S, Padro JI, Paul DM, George DR, Patil A, Rai S, Graubert TA, Bailis JM, You Z, Walter MJ. Nonsense-Mediated RNA Decay Is a Targetable Vulnerability in Splicing Factor Mutant Myeloid Neoplasms by Enhancing R-Loop Accumulation and DNA Damage. Cancer Res. 2026 07 15; 86(14):3537-3553.
-
Hoff FW, Zeidner JF, Torlapati G, Nicolet D, Mrózek K, Huang Y, Li A, Welkie RL, Swords RT, Traer E, Stein EM, Lin TL, Baer MR, Duong VH, Blum WG, Arellano ML, Stock W, Odenike O, Olin RL, Smith CC, Schiller GJ, Curran EK, Chan O, McMahon C, Hochman M, Sahasrabudhe K, Foucar C, Gonzalez-Lugo J, Knick Ragon B, Handa SV, Heerema NA, Chen T, Martycz M, Stefanos M, Marcus SG, Rosenberg L, Druker BJ, Levine RL, Burd A, Yocum AO, Borate UM, Mims AS, Eisfeld AK, Byrd JC, Madanat YF. Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA. Am J Hematol. 2026 Sep; 101(9):2246-2257.
-
Pollyea DA, Altman JK, Assi R, Bachiashvili K, Bhatt VR, Fathi AT, Fedorov K, Foran JM, Gojo I, Goldberg A, Hall AC, Jonas BA, Levine MR, Mangan J, Mannis G, Marcucci G, Mims A, Moriarty K, Mustafa Ali M, Neff J, Nejati R, Olin R, Patel A, Percival ME, Perl A, Pettit K, Rao D, Ravandi F, Schwabkey Z, Shallis R, Stahl M, Stone RM, Thota S, Uy GL, Walker A, Wang E, Awotiwon A, Roth SL, Stehman K. NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026. J Natl Compr Canc Netw. 2026 Jun; 24(6):222-229.
-
Hurvitz N, Amitai I, Yurkovski IL, Tvito A, Ofran Y, Porges T, Wolach O, Sherban A, Even-Zohar NG, Vainstein V, Haran A, Aumann S, Mikhelashvili R, Frisch A, Nachmias B. MRD conversion during oral azacitidine maintenance correlates with outcomes in predominantly favorable-risk AML. Ann Hematol. 2026 May 09; 105(7).
-
Zheng DJ, Hettinger G, Aftandilian C, Bona K, Caywood EH, Collier AB, Elgarten CW, Gathers C, Ghosh T, Gramatges MM, Henry M, Huang YV, Li Y, Lotterman C, Maloney K, Mian A, Miller TP, Modi A, Mody R, Morgan E, Myers R, Newman H, Ortiz J, Seif AE, Smith C, Stokke J, Wang X, Winick N, Wilkes JJ, Wong V, Aplenc R, Getz KD. Real-world generalizability of clinical trial cytomolecular risk in pediatric acute myeloid leukemia: a report from the REAL-AML cohort. J Natl Cancer Inst. 2026 Apr 01; 118(4):746-750.
-
Wang K, Saniei S, Poddar N, Martinez IG, Chao C, Autar S, Fiore P, Carcamo S, Sreenath M, Peplinski JH, Ries RE, Mei AH, Rahman NA, Mekerishvili L, Quijada-Álamo M, Freed G, Zhang M, Lachman K, Diaz Z, Gonzalez MM, Zhang J, Pham G, Filipescu D, Berisa M, Balestra T, Wheeler N, Reisz JA, D'Alessandro A, Puleston DJ, Bernstein E, Chipuk JE, Wunderlich M, Tasian SK, Marcellino BK, Glass IA, Sturgeon CM, Landau DA, Chen Z, Papapetrou EP, Izzo F, Meshinchi S, Hasson D, Wagenblast E. Ontogeny Dictates Oncogenic Potential, Lineage Hierarchy, and Therapy Response in Pediatric Leukemia. Cancer Discov. 2026 Mar 02; 16(3):541-570.
-
Ling T, O'Brien C, St-Germain JR, Rondeau V, Shi M, Berman JM, Cepa A, Saez Raez P, Wunderlich M, Carter KM, Stillwell C, Sexton C, Culp-Hill R, Reisz JA, Adeel SA, Zeng AGX, Bansal S, Tsao E, Chen HT, Dick JE, Minden MD, Arruda A, Amaya ML, Tikhonova AN, Hope KJ, D'Alessandro A, Raught B, Jones CL. Glutaredoxin 2 is essential for AML survival through mitochondrial permeability transition pore regulation. Blood. 2026 Feb 19; 147(8):863-876.
-
Jones MK, Sanchez J, Connor M, Julian K, Rezac R, Marciano K, Tobin J, Bosma G, Abbott D, Anttila K, Sohalski C, Belachew A, McMahon C, Kent A, Amaya M, Angelos MG, Schwartz M, Gutman JA, Pollyea DA. Tolerability and Outcomes With Serial Cycles of 28?Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid Leukemia. Am J Hematol. 2026 Apr; 101(4):728-735.
-
Jia A, Zhang X, Zhou JH, Ma Y, Wang J, Gong Y, Song W, Hu H, Yu Y, Yang H, Lu Y, Huang L, Du X, Chang C, Pei S, Li P, Jordan CT, Zhao TJ, Ye H. Dual targeting of SLC25A51 and succinate dehydrogenase selectively depletes mitochondrial NAD+ to eradicate KRAS-driven AML. Cell Metab. 2026 Jun 02; 38(6):1113-1129.e12.
-
Clayfield L, Malik D, Whittle J, Xu J, Mevel R, Fadlullah MZH, Patel R, Szpakowska M, Maqbool MA, Jones M, Lie-A-Ling M, Chevigne A, Paggetti J, Moussay E, Baker SM, Iqbal M, Maire P, Somervaille TCP, Ford HL, Kouskoff V, Largeot A, Lacaud G. Retinal determination network reactivation drives chemoresistance and blocks myeloid differentiation in acute myeloid leukemia. Cell Rep. 2026 Feb 24; 45(2):116875.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|